Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)

BeaconMedIC has 15 videos Subscribe Here

Description: Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
Shared By : BeaconMedIC
Posted on : 10/20/17
Added : 1 month ago

More From BeaconMedIC

Nothing found.